RCM Technologies, Inc. (RCMT) Declines More Than Market: Some Information for Investors
RCM Technologies, Inc. (RCMT) closed at $22.60 in the latest trading session, marking a -1.18% move from the prior day. This change lagged the S&P 500's 1.13% loss on the day. Meanwhile, the Dow lost 1.79%, and the Nasdaq, a tech-heavy index, lost 1.3%.
The company's stock has dropped by 1.85% in the past month, falling short of the Business Services sector's gain of 0.81% and the S&P 500's gain of 3.55%.
The investment community will be paying close attention to the earnings performance of RCM Technologies, Inc. in its upcoming release. The company is forecasted to report an EPS of $0.6, showcasing a 7.14% upward movement from the corresponding quarter of the prior year. Simultaneously, our latest consensus estimate expects the revenue to be $78.15 million, showing a 13% escalation compared to the year-ago quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $2.19 per share and a revenue of $313.89 million, representing changes of +7.88% and +12.76%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for RCM Technologies, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. As of now, RCM Technologies, Inc. holds a Zacks Rank of #3 (Hold).
Looking at its valuation, RCM Technologies, Inc. is holding a Forward P/E ratio of 10.44. This denotes a discount relative to the industry average Forward P/E of 16.13.
The Staffing Firms industry is part of the Business Services sector. This industry, currently bearing a Zacks Industry Rank of 219, finds itself in the bottom 11% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
RCM Technologies, Inc. (RCMT) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
34 minutes ago
- Indianapolis Star
New to The Street Episode #671 Airs Tonight on Bloomberg Television at 6:30 PM EST Featuring FLOKI, Arrive AI (NASDAQ: ARAI), Health In Tech (NASDAQ: HIT), Vita Bella, and NRX Pharmaceuticals (NASDAQ: NRXP)
This week's episode is sponsored by The Sustainable Green Team's Waterless Garden (OTC:SGTM) and PetVivo Holdings, Inc.'s (NASDAQ:PETV) innovative SPRYNG™ product. NEW YORK CITY, NY / ACCESS Newswire / June 14, 2025 / New to The Street, the nationally syndicated business television series known for spotlighting innovation across sectors, announces the premiere of Episode #671 airing tonight on Bloomberg Television at 6:30 PM EST. This week's broadcast features five dynamic companies making waves across blockchain, AI, health tech, wellness, and pharmaceutical sectors: FLOKI – The globally recognized crypto and blockchain brand building Web3 utility through its DeFi ecosystem. Arrive AI (NASDAQ:ARAI) – Developer of a patented smart mailbox delivery platform, leading last-mile logistics innovation with its autonomous, AI-powered systems. Health In Tech (NASDAQ:HIT) – A pioneer in digital underwriting and quote-to-card technology for health insurance, transforming how plans are built and priced. Vita Bella – A wellness brand that continues to expand its national presence through health-focused lifestyle offerings. NRX Pharmaceuticals (NASDAQ:NRXP) – A late-stage pharmaceutical company advancing treatments for CNS disorders and respiratory distress. This week's featured corporate sponsors include: The Sustainable Green Team (OTC:SGTM) and its revolutionary Waterless Garden initiative for drought-resistant, sustainable landscaping. PetVivo Holdings, Inc. (NASDAQ:PETV), showcasing continued progress with its SPRYNG™, a veterinary injectable device for treating osteoarthritis in companion animals. Upcoming Highlights: New to The Street has also wrapped filming this week with several prominent brands: GLINT Pay (Private) – A disruptive gold-as-money platform allowing real-time gold transactions. Lahontan Gold Corp. (TSX.V:LG / OTCQB:LGCXF) – Canadian gold exploration company with high-grade assets in Nevada. Greer Consulting Group – Providing strategic solutions across regulatory compliance, M&A, and executive strategy. Special Feature Segment: A culinary showcase from two of New York City's most iconic dining destinations – Black Barn and Hunt & Fish Club – blending luxury hospitality with the business of restaurant branding. Additionally, special segments fromIMG Academy, Skip Barber Racing School, and KITON will continue to roll out in the coming months as part of New to The Street's ongoing coverage of elite performance, luxury, and innovation. Quote from Vince Caruso, Creator and Executive Producer of New to The Street: 'We continue to be a destination for innovative and publicly traded companies ready to tell their story at scale. Tonight's show blends AI, healthcare, crypto, and wellness with real national TV exposure. We're proud to feature these brands and grateful to our show sponsors for helping amplify their messages.' About New to The Street Since 2009, New to The Street has become one of the most trusted platforms for public and private companies to share their stories. The show combines sponsored programming with earned media, enhanced by iconic outdoor campaigns, nationwide TV commercials, and non-deal roadshows that connect executives with top-tier investors and institutions. With weekly reach across 220 million linear TV households, a growing 2.65 million YouTube subscribers, and a robust social media presence exceeding 700,000 followers across LinkedIn, Facebook, Instagram, and X, New to The Street delivers unparalleled exposure and credibility in the business media space. For more information, visit SOURCE: New To The Street View the original press release on ACCESS Newswire
Yahoo
35 minutes ago
- Yahoo
OKYO Pharma Limited's (NASDAQ:OKYO) market cap up US$38m last week, benefiting both individual investors who own 58% as well as insiders
OKYO Pharma's significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public 42% of the business is held by the top 12 shareholders Insider ownership in OKYO Pharma is 36% We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. A look at the shareholders of OKYO Pharma Limited (NASDAQ:OKYO) can tell us which group is most powerful. We can see that individual investors own the lion's share in the company with 58% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Following a 58% increase in the stock price last week, individual investors profited the most, but insiders who own 36% stock also stood to gain from the increase. Let's take a closer look to see what the different types of shareholders can tell us about OKYO Pharma. View our latest analysis for OKYO Pharma Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index. As you can see, institutional investors have a fair amount of stake in OKYO Pharma. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of OKYO Pharma, (below). Of course, keep in mind that there are other factors to consider, too. We note that hedge funds don't have a meaningful investment in OKYO Pharma. Gabriele Marco Cerrone is currently the largest shareholder, with 29% of shares outstanding. For context, the second largest shareholder holds about 6.8% of the shares outstanding, followed by an ownership of 5.9% by the third-largest shareholder. Our studies suggest that the top 12 shareholders collectively control less than half of the company's shares, meaning that the company's shares are widely disseminated and there is no dominant shareholder. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage. While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group. Our information suggests that insiders maintain a significant holding in OKYO Pharma Limited. Insiders have a US$37m stake in this US$102m business. It is great to see insiders so invested in the business. It might be worth checking if those insiders have been buying recently. The general public, who are usually individual investors, hold a substantial 58% stake in OKYO Pharma, suggesting it is a fairly popular stock. This level of ownership gives investors from the wider public some power to sway key policy decisions such as board composition, executive compensation, and the dividend payout ratio. I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. To that end, you should learn about the 4 warning signs we've spotted with OKYO Pharma (including 2 which make us uncomfortable) . If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
an hour ago
- Yahoo
3 No-Brainer Artificial Intelligence (AI) Growth Stocks to Buy With $200 Right Now
Artificial intelligence (AI) stocks have led the S&P 500 higher over the last two and a half years. These three stocks trade at relatively low valuations compared to other high-flying AI stocks. They each have meaningful upside across the board, from AI software to hardware to chip manufacturing. 10 stocks we like better than Alphabet › Artificial intelligence (AI) has become one of the most-talked-about topics on Wall Street over the last two and a half years. More than 40% of S&P 500 (SNPINDEX: ^GSPC) companies have cited "AI" on their earnings calls for five straight quarters, according to FactSet Insight. Practically every business is looking at how the recent innovations and influx of spending on AI can impact just about every aspect of their business. But while AI is providing a ton of growth for some, it can be a cost center without a clear payoff for others. However, even if a company falls into the former camp, investors should be wary about overpaying for growth that could slow down as the business scales. Finding good value in AI stocks isn't easy. And if you have a limited investment budget, like $200, you'll want to make sure you're only buying the best available options. These three companies all have stocks that trade for less than $200 per share and offer excellent value for the growth potential ahead of them. All three are benefiting from the growth of AI and should play important roles in the future development of artificial intelligence and computing from here. Many investors are worried about the impact of artificial intelligence on Alphabet's (NASDAQ: GOOG) (NASDAQ: GOOGL) core Google Search product. Apple's Eddy Cue testified that search queries were down on its Safari browser during the month of April for the first time in 22 years, supporting the idea that AI services like ChatGPT are eating into its market share. But a decline in searches on a single browser, while surprising, isn't too concerning. AI is a bigger boost to Alphabet than a challenge. It's seen great success with its AI Overviews in search queries, which management says increase engagement while monetizing at the same level as traditional search results. It's also leveraged AI to offer new features like circle-to-search and Google Lens, which overindex toward valuable product searches. Artificial intelligence has been a massive driver of growth for Alphabet's Google Cloud business. It saw revenue climb 28% in the first quarter, with its operating margin expanding from 9.4% to 17.8%. Management said it remains supply-constrained, so strong revenue growth should continue. On top of that, Google's bigger cloud computing competitors sport even higher operating margins, so there's room to expand profits as it scales. At about $177 per share, the stock trades for about 18.5 times forward earnings expectations. That's well below comparable stocks, but Alphabet does have some regulatory pressure on its business on top of worries about how AI could negatively impact its cash flow. But with a massive cash-flowing business, an increasingly profitable cloud computing business, and a big capital return program, the stock looks very attractive at this level. Qualcomm (NASDAQ: QCOM) isn't the chipmaker many people think of when they're talking about AI chip stocks. It doesn't make high-end GPUs or custom silicon solutions for AI training or inference. It makes chips that primarily end up in smartphones. But Qualcomm has plans to enter the data center business, focusing on CPUs designed to work in tandem with AI accelerator chips. It believes its expertise in low-power, high-performance chips for smartphones will translate into very effective chip designs for data centers. It recently agreed to acquire Alphawave Semi with the aim of bolstering its data center capabilities. The company will face significant competition in that market, but not all AI inference will take place in the cloud. There's a growing push to perform AI processing on devices themselves, which provides advantages in security, privacy, and speed. To that end, Qualcomm is well-positioned to see a growing share of the market, as its Snapdragon mobile processors are found in most high-end Android devices. As on-device AI becomes a differentiator, demand for high-end devices could increase, boosting Qualcomm's mobile processor sales. In the meantime, Qualcomm holds the patents for wireless baseband chips found in practically every phone. As a result, it collects a royalty for every smartphone sale. Apple is notably moving away from Qualcomm, developing its own chipsets, but the process is a big hurdle. Few other phone makers have the capability, capital, or scale necessary to cut out Qualcomm. As such, the licensing business should provide a stable source of earnings for the business for the foreseeable future. At around $160 per share, the stock trades for just 13.5 times forward earnings. That's an incredible value for a company with strong long-term positions in Android phones, and it seems Apple's moves are weighing too heavily on the stock. With a potential data center business on the horizon, it could have another big business like its mobile processors. But even with just the mobile chips and licensing business producing steady free cash flow, it's still a great value at this price. While cloud computing providers are trying to stock their data centers with more and more chips for artificial intelligence training and inference, somebody has to make those chips. And in order to do that, you need specialized equipment. That's where Applied Materials (NASDAQ: AMAT) comes in. The company produces a broad portfolio of wafer fabrication equipment, including etching, deposition, and process control. Applied Materials' ability to participate in all of those areas gives it an advantage. It can cross-sell manufacturers on its equipment, allowing it to compete with more specialized equipment makers. And as one of the largest equipment providers, it also has more revenue to reinvest in R&D to produce the next generation of equipment or expand its portfolio, creating a virtuous cycle and extending its technology lead. The push to expand chip production has been a boon for Applied Materials. Despite sales restrictions in China and slower growth in the automotive segment, the equipment maker grew sales 7% in the first quarter. The shift toward more high-end devices also helped expand its gross margin to over 49% last quarter. Applied Materials' product is extremely sticky, too. Once a manufacturer buys its equipment, it wants to get the most out of it. That means a long product life and recurring service revenue. With the stock trading at about $175 per share, it sports a forward P/E of about 18.5. That's a great value for a company growing revenue at a steady high-single-digit clip with expanding margins. While the business can be cyclical, the long-term trend is for more and more advanced chip sales. Applied Materials is well-positioned to capitalize on that trend, and its current stock price gives investors a great opportunity to buy into it. Before you buy stock in Alphabet, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Alphabet wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $655,255!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $888,780!* Now, it's worth noting Stock Advisor's total average return is 999% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Adam Levy has positions in Alphabet, Apple, Applied Materials, and Qualcomm. The Motley Fool has positions in and recommends Alphabet, Apple, Applied Materials, and Qualcomm. The Motley Fool has a disclosure policy. 3 No-Brainer Artificial Intelligence (AI) Growth Stocks to Buy With $200 Right Now was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
